Programmed Death‐Ligand 1 Expression Predicts Poor Prognosis in Patients With Early‐Stage Non‐Small‐Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy
Thoracic Cancer · 2026-05 · 17 (9)
DOI: 10.1111/1759-7714.70296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 01.05.2026. Verfasst von Jongmoo Park und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, School of Medicine, Kyungpook National University, Daegu, South Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiosurgery, B7-H1 Antigen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yeungnam University.
Abstract (Originalsprache)
Background
Stereotactic body radiotherapy (SBRT) is the standard treatment for medically inoperable early‐stage, non‐small‐cell lung cancer (NSCLC). Programmed death‐ligand 1 (PD‐L1) is a well‐known biomarker for predicting immunotherapy responses; however, its prognostic significance in early‐stage NSCLC treated with SBRT remains unclear. Here, we evaluated the prognostic significance of PD‐L1 expression in this setting.
Methods
We retrospectively analyzed patients with early‐stage NSCLC who underwent SBRT. PD‐L1 expression was assessed using the SP263 immunohistochemistry assay and quantified by tumor proportion score. We evaluated the prognostic impact of PD‐L1 as a continuous variable and used an exploratory 2% cutoff derived from receiver operating characteristic analysis. Clinical outcomes, including local recurrence‐free survival (LRFS), recurrence‐free survival (RFS), disease‐free survival (DFS), and overall survival (OS), were compared. Cox proportional hazards models were used for multivariable analysis.
Results
A total of 54 patients were included. SBRT achieved a 2‐year LRFS rate of 98%. As a continuous variable, higher PD‐L1 expression was independently associated with inferior RFS (hazard ratio (HR): 1.07, p < 0.01), DFS (HR: 1.06, p < 0.01), and OS (HR: 1.04, p < 0.01). The PD‐L1‐positive group had a higher incidence of regional recurrence (30.0% vs. 5.9%, p = 0.041). The exploratory 2% cutoff identified a subgroup with significantly worse survival in univariable analyses, although it did not retain independent significance in the multivariable analysis.
Conclusions
PD‐L1 expression is independently associated with worse survival outcomes in patients with early‐stage NSCLC treated with SBRT, indicating its potential as a prognostic biomarker for risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, School of Medicine, Kyungpook National University, Daegu, South Korea.
- Department of Radiation Oncology, Yeungnam University College of Medicine, Daegu, South Korea.
ORCID-Profile: Jaehyeon Park
Förderung
- Yeungnam University
Zitieren
APA
Park, J., Yea, J. W., Park, J. W., Jo, Y. Y., Oh, S. A., & Park, J. (2026). Programmed Death‐Ligand 1 Expression Predicts Poor Prognosis in Patients With Early‐Stage Non‐Small‐Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy. Thoracic Cancer, 17(9). https://doi.org/10.1111/1759-7714.70296
Vancouver
Park J, Yea JW, Park JW, Jo YY, Oh SA, Park J. Programmed Death‐Ligand 1 Expression Predicts Poor Prognosis in Patients With Early‐Stage Non‐Small‐Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy. Thoracic Cancer. 2026;17(9). doi:10.1111/1759-7714.70296
BibTeX
@article{Park2026,
author = {Park, Jongmoo and Yea, Ji Woon and Park, Jae Won and Jo, Yoon Young and Oh, Se An and Park, Jaehyeon},
title = {Programmed Death‐Ligand 1 Expression Predicts Poor Prognosis in Patients With Early‐Stage Non‐Small‐Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {9},
doi = {10.1111/1759-7714.70296}
}
EUVIMED